Vaso Corporation Announces Financial Performance Highlights
In a recent announcement, Vaso Corporation (OTCQX: VASO), a prominent player in the MedTech industry, revealed robust financial results for the quarter ending September 30, 2025. The company has a diverse portfolio that spans network and healthcare IT services, professional sales, and proprietary medical products.
Strong Revenue Growth
For the third quarter of 2025, Vaso Corporation reported total revenues reaching $22.7 million, marking a significant increase of $1.9 million or 9.1% from $20.8 million in the same quarter of the previous year. Dr. Jun Ma, the company’s President and CEO, emphasized that all segments of the business contributed positively to this impressive increase in revenue.
Dr. Ma stated, "This quarter’s net income improved to $1.7 million, recovering from a net loss of $1.2 million during the same period last year. This turnaround reflects higher revenue levels, improved gross margins, and reduced operating expenses." The company’s enhanced financial health signals a promising trajectory in its operational strategy.
Cash Flow and Financial Health
During the quarter, cash generated from operating activities was reported at $2.8 million, bolstering the company's balance sheet. Vaso Corporation holds cash and cash equivalents amounting to $34.9 million as of the quarter's end. Additionally, deferred revenue shows a positive trend, and subscription revenues have become a significant component of total income, providing stability for the future.
Quarterly Financial Breakdown
Let's delve deeper into the financial results for the three months ending September 30, 2025:
- Total Revenue: Increased by 9.1% to $22.7 million.
- Gross Profit: Rose by $2.1 million to $13.9 million, corresponding to an 18.2% rise compared to the previous year.
- SG&A Expenses: Slightly increased by $803 thousand to $12.2 million, mainly due to higher personnel costs.
- Operating Income: Improved to $1.5 million from an operational loss of $1.4 million last year.
- Net Income: Recorded at $1.7 million, in comparison to the previous year’s net loss.
- Adjusted EBITDA: Marked at $1.6 million, a turnaround from a negative $1.2 million in the same quarter last year.
Outlook and Future Strategies
With a strong quarterly performance, Vaso Corporation is well-positioned for continued growth. The upcoming Annual Shareholders Meeting, taking place in December, will shed more light on the company’s strategies and outlook, as they look forward to gaining further momentum in the market.
About Vaso Corporation
Vaso Corporation specializes in managed IT systems and services, providing innovative healthcare software solutions, and extensive network connectivity services. The company also engages in the professional sale of medical equipment and the design, manufacture, and sale of proprietary medical devices.
Vaso operates through three key subsidiaries:
- VasoTechnology, Inc. - Focused on providing network and IT services.
- Vaso Diagnostics, Inc. - Engaged in professional sales services for GE HealthCare's diagnostic imaging products.
- VasoMedical, Inc. - Manages the design and manufacturing of proprietary medical equipment.
Frequently Asked Questions
What were Vaso Corporation's total revenues for the quarter?
Total revenues for the third quarter of 2025 were $22.7 million.
How has Vaso Corporation's net income changed from last year?
The net income rose to $1.7 million from a loss of $1.2 million in the same period last year.
What is Vaso Corporation’s Adjusted EBITDA for the quarter?
Adjusted EBITDA for the third quarter was $1.6 million, improving from a negative $1.2 million last year.
When will the Annual Shareholders Meeting occur?
The Annual Shareholders Meeting is scheduled for December.
What are the key segments of Vaso Corporation's business?
Vaso operates in managed IT services, professional sales for medical equipment, and the design and manufacturing of proprietary medical devices.
